Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), an emerging growth company incorporated in Florida. The report covers events occurring on November 14, 2025, with the filing signed on November 20, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Craig Eagle from the Company's Board of Directors, effective immediately on November 14, 2025. The Company explicitly states that the resignation was not the result of any disagreement with the Company, its management, or other Board members.
Outlook, Risks, and Management Commentary
Management expressed gratitude for Mr. Eagle's service. No forward-looking guidance, financial outlook, or new risk factors were disclosed in this filing. The resignation letter is attached as Exhibit 17.1.
Key Facts for Investor Verification
- Confirm the current composition of the Board of Directors following Mr. Eagle's departure.
- Review the attached resignation letter (Exhibit 17.1) for any additional context not summarized in the 8-K.
- Verify if the Board has announced plans to nominate a replacement director.
- Check subsequent filings for any impact on the Company's strategic direction or operations.